HCW Biologics Inc

For the period ended Mar 31, 2024. Filed May 15, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

HCWB$1.02-1.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of changes in stockholders’ equity

Condensed Statements of Changes in Stockholders’ Equity

For the Three Months Ended March 31, 2023 and 2024

	Stockholders’ Equity
Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Deficit	Equity
Balance, December 31, 2022	35,876,440	$3,588	$82,962,964	$(45,538,046)	$37,428,506
Issuance of Common Stock upon exercise of stock options	10,195	1	1,900	—	1,901
Stock-based compensation	—	—	259,206	—	259,206
Net loss	—	—	—	(5,070,686)	(5,070,686)
Balance, March 31, 2023	35,886,635	$3,589	$83,224,070	$(50,608,732)	$32,618,927

	Stockholders’ Equity
Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’
Shares · Amount · Capital · Deficit · Equity
Balance, December 31, 2023	36,025,104	$3,603	$83,990,437	$(70,532,323)		$13,461,717
Issuance of Common Stock upon exercise of stock options	12,572	1	2,254	—		2,255
Issuance of Common Stock upon equity subscription	1,785,718	178	2,499,827		2,500,005
Stock-based compensation	—	—	244,685	—		244,685
Net loss	—	—	—	(7,468,061)		(7,468,061)
Balance, March 31, 2024	37,823,394	$3,782	$86,737,203	$(78,000,384)		$8,740,601

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.